# Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer

> **NCT05810792** · PHASE2 · NOT_YET_RECRUITING · sponsor: **Sahlgrenska University Hospital** · enrollment: 50 (estimated)

## Conditions studied

- Pancreatic Cancer
- Surgery
- Metastasis
- Immunosuppression

## Interventions

- **DRUG:** Histamine Dihydrochloride (HDC)
- **DRUG:** Interleukin-2 (IL-2)

## Key facts

- **NCT ID:** NCT05810792
- **Lead sponsor:** Sahlgrenska University Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-01
- **Primary completion:** 2027-04-01
- **Final completion:** 2028-04-01
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-11-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05810792

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05810792, "Histamine Dihydrochloride and Interleukin-2 in Primary Resectable Pancreatic Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05810792. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*